Scientist, Lcms, Gcms, Hplc, Mass Spectrometry, Dmpk, Adc, Peptide

William J. Bodell PhD

Cell: 510-***-**** email: ********@*****.***

Overview:

I am a bioanalytical scientist with over 15 years of experience in the application of liquid chromatography and mass spectrometry to quantitative measurements of drug levels and their metabolites. I develop robust analytical methods to accurately and rapidly perform preclinical drug analysis. I am looking for a new position to develop and apply quantitative methods to measurement of small molecules, peptides and antibody drug conjugates.

Education:

B.S.: Chemistry, University of Nebraska, Lincoln, NE.

Ph.D.: Life Sciences-Biochemistry. University of Nebraska, Lincoln, NE.

KEY SKILLS

Develop and conduct analytical methods which are in accordance with FDA Bioanalytical Method Validation for Industry Pharmacokinetic analysis of compounds with Phoenix Win Non Lin.

Application of QQQ and Q-TOF mass spectrometers for quantitative analysis of small molecules, peptides and ADC compounds and their metabolites in plasma.

Perform microsomal metabolism, hepatocyte stability and Met ID studies on drug candidates.

Conjugation of antibodies with linker-payloads using maleimide reagents. Measurement of ADC stability and linker payload release.

Work Experience:

FormaPath San Francisco, CA 6/23-12/24

Consultant

Providing consultation on sample preparation of surgical pathology samples for analysis by mass spectrometry.

Olema Oncology San Francisco, CA 10/21-3/23

Senior Scientist II

Established the Bioanalytical Lab at Olema Oncology. Performed the DMPK analysis of Olema’s lead compounds. This work included sample preparation and development of UPLC and MS acquisition methods with Shimadzu-Sciex 7600 QTOF. The levels of Olema’s investigational compounds were measure in plasma, brain and tumor samples. The results of the quantitative studies were used to calculate PK parameters of the investigational agents.

Accomplished: These studies developed robust accurate methods for rapid analysis of samples for pharmacokinetic drug analysis.

Abbott Laboratories Santa Rosa, CA 1/20- 9/21

Senior Scientist II

Developed validated mass spectrometry based screening methods for quantification of drugs and their metabolites according to Standard Practices for Method Validation in Forensic Toxicology. Extraction of analytes from matrices with SPE AND LLE. Used Shimadzu-Sciex 4500 Q Trap for sample analysis. Sciex Analyst and Mutiquant software platforms for data acquisition and data analysis.

Accomplished: This work lead to the development of multiple validated methods for quantitative clinical drug screening.

Real Remedy Emeryville, CA 08/18- 09/19

Chemist

Developed and applied Chemistry Manufacturing Controls for purity and stability testing of API, drug substance, and impurity analysis. These studies used Agilent 1210 LC\UV for the quantitative studies. Instrument control was Agilent Chemstation..

Accomplished: These investigations lead to the development of multiple methods for quantitative characterization of the company prior to their commercial release.

Genentech San Francisco, CA 03/16-11/16

Contract Scientist

Perform LC/MS/MS using Shimadzu-Sciex 6500 triple quad and Sciex 6600 QToF for quantification of investigational agents and their metabolites in plasma, or tissue extracts. Sciex Analyst and Mutiquant software platforms for data acquisition and data analysis. Development of multiple biomarker studies..

Quantification of ADCs with trypsin digestion and use of stable isotope labeled peptides. Measured ADC stability, linker and payload release. These studies better characterized the ADC being developed.

Accomplished: These studies developed multiple biomarkers for analysis of therapeutic response and pharmacokinetic analysis of ADC compounds.

Comprehensive Pain Management Clinic Campbell, CA 10/13-02/16

Analytical Chemist

Developed and validated GC/MS methods for the quantification of opiates and benzodiazepines and their metabolites in urine of pain management patients. These studies were carried out by the Federal Code of Regulations Title 42 Part 493 Laboratories performing high complexity testing. Detection and Quantification of analytes were performed with Agilent 7820/5977 GC-EI-MSD using Agilent Mass Hunter software.

Accomplished: The developed methods were used to screen thousands of urine samples.

Contrast Therapeutics Richmond, CA 6/06-6/13

Scientist

Developed platforms for the synthesis of small molecule therapeutic agents which were detected by CT imaging.

Screened the drug candidates in human brain tumor cell lines for their in vitro cytotoxicity.

Accomplished: These studies lead to the development of drugs which were both therapeutic and also detected by clinically used imaging technologies.

University of California San Francisco, CA 1/95-5/06 Investigator Brain Tumor Research Center, Dept of Neurological Surgery

Investigated molecular mechanisms of drug sensitivity and resistance in glioma tumors and developed treatments to overcome drug resistance.

Developed surrogate biomarkers of drug delivery and therapeutic effectiveness for CNS tumors treated with Carmustine. Analyzed clinical samples of human brain tumors for drug delivery and distribution.

Performed laboratory studies supporting the development of new clinical trials with existing FDA approved therapeutic agents.

Identified the structures of DNA adducts formed by chemotherapeutic, occupational and environmental agents

Accomplished: These studies identified the structures of DNA adducts formed by chemotherapeutic agents Carmustine, Tamoxifen, and environmental (Benzene) agents. From this work, we developed analytical methods to measure DNA adducts formed by these agents in clinical samples and in animal models.

Patent

William J Bodell, Synthesis of Chemotherapeutic Agents Detected by CT Imaging. Provisional Patent 11/18/2016

Selected Publications from 102 Peer Reviewed Publications.

Alison D. Parisian; Gopinath S. Palanisamy; Fabian Ortega; Judevin L. Sapugay; William J. Bodell; David Kulp; Peter Kushner; Cyrus Harmon. Combination of complete estrogen receptor antagonist, OP-1250, and CDK4/6 inhibitors enhances tumor suppression and inhibition of cell cycle-related gene expression . Cancer Res (2023) 83 (5_Supplement): P2-24-07

Gaikwad NW, Bodell WJ. Peroxidase-mediated dealkylation of Tamoxifen, detected by electrospray ionization-mass spectrometry, and activation to form DNA adducts. Free Radic Biol Med. 2012 Jan 15;52(2):340-347

Contact this candidate